Body Temperature And Blood Pressure Are Prerequisites For Someone To Get Vaccines, See The Explanation
JAKARTA - The COVID-19 vaccination program to prevent transmission in the community will be carried out this January, after an emergency use authorization (UEA) permit is issued by the Food and Drug Supervisory Agency (BPOM).
Although this vaccination will be given evenly, based on the official technical guidelines for the implementation of vaccination issued by the Ministry of Health, there are people who are required to postpone or not receive the Sinovac vaccine.
Quoted from the technical guidelines for the Ministry of Health on page 16, the Association of Indonesian Internal Medicine Specialists (PAPDI) explained several criteria for people who should be postponed or not given the Sinovac vaccine, namely:
If based on the measurement of the body temperature of the potential vaccine recipient with a fever or above 37.5 degrees Celsius, vaccination is postponed until the patient has recovered and is proven not to have COVID-19 and is re-screened at the time of the next visit. If the measurement of blood pressure is above 140/90, then vaccination is not given. For those who have had COVID-19, are pregnant or breastfeeding, have suffered from symptoms of ARI in the last seven days, have a history of severe allergies, kidney disease, rheumatism, chronic gastrointestinal tract pain, vaccination is not given. For people with HIV, if the CD4 count is less than 200 or even unknown, the vaccination is not given. If the patient has lung diseases such as asthma, COPD, and tuberculosis then vaccination is postponed until the patient's condition is well controlled. For TB patients in treatment, vaccinations can be given at least two weeks after receiving anti-tuberculosis drugs.Meanwhile, for people who have diabetes, the association's recommendation says, people with diabetes mellitus or type 2 diabetes mellitus are controlled with HbA1C below 58 mmol / mol or 7.5 percent can be vaccinated.
As for other diseases that are not mentioned, you can first consult with the doctor who carries out the treatment.
In the same technical guidelines, the Ministry of Health also describes three priority groups of people who get vaccinated according to the WHO Strategic Advisory Group Roadmap of Experts on Immunization (SAGE), namely:
Health workers who are at high to very high risk for infection and transmitting SARS-CoV-2 in the community Groups at risk of death or serious illness (comorbid) Social / occupational groups who are at high risk of contracting and transmitting the infection because they cannot effectively distance themselves (public officer)Furthermore, because the vaccine supply will not be available to meet all targets, based on the roadmap prepared by the WHO Strategic Advisory Group of Experts on Immunization (SAGE), there are three scenarios for vaccine supply that are considered by countries:
Phase I when vaccine availability is very limited (ranging from 1-10 percent of the total population of each country) to initial Phase II distribution when vaccine supply increases but availability remains limited (range between 11-20 percent of the total population of each country) Stage III when supply vaccines reach moderate availability (ranging from 21-50 percent of the total population of each country)Previously reported, the Chairperson of the Committee for Handling COVID-19 and National Economic Recovery (KPCPEN) Airlangga Hartato said that the COVID-19 vaccination could be carried out in mid-January as long as BPOM issued an emergency use authorization (EUA) for the Sinovac vaccine that had been imported to Indonesia as many as 3 million of these doses.
"The government will immediately initiate vaccinations scheduled for the middle of the month or next week. This is of course awaiting emergency use authorization from the POM," said Airlangga in the Presidential Secretariat Youtube broadcast, Monday, January 4.
Airlangga said that the EUA permit for the Sinovac vaccine would be issued after seeing the data on the results of the third phase of clinical trials conducted in Bandung and a number of other countries such as China, Turkey and Brazil. Not only that, the implementation of vaccination is also still awaiting the results of a study from the halal aspect by the Institute for the Assessment of Food, Medicine and Cosmetics, the Indonesian Ulema Council (LPPOM MUI).
"The government is also continuing to prepare various vaccinations for procurement, both AstraZeneca, Pfizer, Novavax, and GAVI," said Airlangga.